Menarini to take on external chairman

29 March 2018

Menarini, one of Italy’s largest pharma companies and still headed by the founding Aleotti family, has decided to entrust the chairmanship of the company to an external manager coming from a large multinational, Dr Eric Cornut.

The new chairmanship will come into effect as of June. Between 1989 and 2016, Dr Cornut held various senior executive positions with Swiss pharma giant Novartis (NOVN: VX) and its component company Ciba-Geigy. Currently an independent consultant based in Basel, Switzerland, he also served as an interim director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA) from September 2016 until April 2017. Additionally, Dr Cornut has been a member of the boards of Germany’s Stada Arzneimittel and of Switzerland’s Helsinn Healthcare.

The announcement was made by Lucia Aleotti herself, current chairman of the Menarini group, together with her brother, Alberto Giovanni, vice chairman.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK